Dr. Enoche Oga

Lecturer in Pharmaceutics

School of Pharmacy and Biomedical Sciences

Maudland Building, MB024

+44 (0) 1772 89 5842

Dr. Oga’s main research interests lie in biopharmaceutics, drug delivery systems, pharmacokinetics (including that of complementary and alternative medicines) as well as models for drug metabolism & pharmacokinetics

Teaching Activities and Responsibilities

Enoche teaches pharmaceutics modules on the MPharm programme, MSc Industrial Pharmaceutics and MSc Cancer Biology courses. This spans modules on Dosage forms 1 (L4), Dosage forms 2 (L5), Biopharmaceutics (L6), Drug development (L6 and L7), Advanced drug delivery (L7), Applied biopharmaceutics (L7), Practical techniques in Industrial pharmaceutics/Medicinal chemistry (L7), Pharmaceutical technology & formulation development (L7), Pharmaceutical regulations, clinical trials & pharmacovigilance (L7) and Drug design and delivery (L7)

Dr. Oga is the module leader for Dosage forms 2 (L5) and Advanced Drug Delivery Systems (L7)


Ph.D. Pharmaceutical Science, Chiba University- Japan
B.Pharm (Distinction), University of Jos- Nigeria


Oga E. F., Sekine S. and Horie T (2013). Drug Metabolism and Pharmacokinetics. 28(4):314-320

Oga E. F., Sekine S., Shitara Y. and Horie T. (2012). American Journal of Tropical Medicine and Hygiene. 87(1);64-69

Oga E. F., Sekine S., Shitara Y. and Horie T. (2012). Journal of Ethnopharmacology.144 (3); 612-617


  • Fellow of the Higher Education Academy
  • Member, International Society for the Study of Xenobiotics
  • Member, American Association of Pharmaceutical Scientists
  • Member, American Association for the Advancement of Science
  • Member, Pharmaceutical Society of Nigeria


  • Investigation of enzyme/transporter inhibition and induction using in vitro and in vivo models.
  • Drug metabolism, metabolite and physicochemical profiling as well as studies assessing preclinical toxicity of drug candidates and herbal remedies
  • Dissolution enhancement and investigating in vitro in vivo correlation
  • Preformulation and early phase development of solid, semisolid & liquid dosage forms
  • Neglected tropical diseases and HIV/AIDS